Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

210 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Follow-up AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - Follow-up AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 17-11-21 - 1 Formulier, 5 Itemgroepen, 22 Data-elementen, 1 Taal
Itemgroepen: Follow-up, Concomitant Disease, Therapy, Allogenic Transplantation, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Rezidiv / Tod EudraCT-Nr 2008-004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3 - Rezidiv / Tod

- 17-09-21 - 1 Formulier, 8 Itemgroepen, 60 Data-elementen, 2 Talen
Itemgroepen: Patientendaten, Differentialblutbild, Knochenmarkuntersuchung, Zytologie, Molekulargenetik, Unterschrift, Patientendaten, Unterschrift
A randomized, multi-center phase II trial to assess the efficacy of 5-azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML

Maintenance AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - Maintenance AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 13-04-21 - 1 Formulier, 6 Itemgroepen, 25 Data-elementen, 1 Taal
Itemgroepen: Maintenance, Dasatinib intake during last month (since last visit), Urinalysis, Adverse Event, Concomitant Medication, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Follow Up AML Pazopanib NCT01361334

- 11-02-16 - 1 Formulier, 1 Itemgroep, 12 Data-elementen, 2 Talen
Itemgroep: Patient status
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Monat 1 Erhaltungstherapie / Nachbeobachtung EudraCT-Nr.: 2008-004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3 - Monat 1 Erhaltungstherapie / Nachbeobachtung

- 16-12-13 - 1 Formulier, 9 Itemgroepen, 79 Data-elementen, 2 Talen
Itemgroepen: Patientendaten, Therapie-Status, ECOG-Status, Differentialblutbild, Klinische Chemie, Knochenmarkuntersuchung, Zytologie, Molekulargenetik, Unterschrift
A randomized, multi-center phase II trial to assess the efficacy of 5-azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML

BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML NCT01488344 - Follow up

- 26-11-17 - 1 Formulier, 2 Itemgroepen, 6 Data-elementen, 1 Taal
Itemgroepen: Follow up, investigator signature
Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) - NCT01488344 https://clinicaltrials.gov/ct2/show/NCT01488344 Principal Investigator PD Dr. Utz Krug RATIONALE: Low-dose cytarabine works in a minority of elderly patients with an acute myeloid leukemia unfit for intensive induction therapy by killing of leukemia cells. Addition of BIBF1120 to low-dose cytarabine might enhance the killing of leukemia cells. PURPOSE: This phase I / II trial is studying how safe BIBF1120 can be combined with low-dose cytarabine (phase I) and how well the combination of low-dose cytarabine and BIBF1120 works in elderly patients with acute myeloid leukemia unfit for intensive chemotherapy (phase II). Study Type: Interventional Study Design: Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Single-arm, Open Label, Multi-center Phase I/II Trial to Assess the Safety and Efficacy of BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML Unfit for an Intensive Induction Therapy

Evaluation AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - Evaluation AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 11-02-16 - 1 Formulier, 5 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Evaluation, Status, Response after Induction Cycles or Consolidation or Maintenance or during Follow-up, Evaluation based on on following examinations, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Newly diagnosed Malignancy AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - Newly diagnosed Malignancy AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 11-02-16 - 1 Formulier, 2 Itemgroepen, 9 Data-elementen, 1 Taal
Itemgroepen: Newly diagnosed Malignancy, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

CALGB: 10603 Follow-Up Form DRKS00003845 NCT00651261 - CALGB: 10603 Follow-Up Form NCT00651261

- 08-06-15 - 1 Formulier, 10 Itemgroepen, 51 Data-elementen, 1 Taal
Itemgroepen: Header, Patient demographics, Treatment Phase Information, Vital Status, Disease Follow-Up Status, Notice of Progression, RECOVERY, Transplant Treatment Plan, Notice of New Primary Cancer, Footer Module
CALGB: 10603 Follow-Up Form NCT00651261 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=43C5D677-EB7A-6D45-E044-0003BA3F9857

Long-Term Follow-up Form Leukemia (NCT00049517)

- 10-01-15 - 1 Formulier, 8 Itemgroepen, 30 Data-elementen, 1 Taal
Itemgroepen: Header, Vital Status, Disease Follow-up Status, Relapse, New Primary, Toxicity, Non-Protocol Therapy, Transfusions
E1900 Long-Term Follow-up Form Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia NCT00049517 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A7294868-3C8F-2FCA-E034-0003BA0B1A09

NCT00049517 Follow-Up - E1900 Cover Page for Acute Leukemia Disease Assessment Form - 2075100v3.0 - E1900 Cover Page for Acute Leukemia Disease Assessment Form

- 09-01-15 - 1 Formulier, 4 Itemgroepen, 12 Data-elementen, 1 Taal
Itemgroepen: Header, On Treatment, Off Treatment, CCRR MODULE
E1900 Cover Page for Acute Leukemia Disease Assessment Form Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B19AB05D-F815-25DE-E034-0003BA12F5E7

Leukemia NCT01041703 Follow-Up - E2906 Long-Term Follow-up Form - 2947429v1.0 - E2906 Long-Term Follow-up Form

- 08-01-15 - 1 Formulier, 9 Itemgroepen, 34 Data-elementen, 1 Taal
Itemgroepen: Header Module/Off-Treatment Report Period, Header, Section 1 - Vital Status, Section II - Reporting Period, Section III - Notice of New Primary, Section IV - Disease Follow-up Status, Section V - Adverse Events, Section VI - Non-Protocol Therapy Prior To Progression, Footer Module
E2906 Long-Term Follow-up Form Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=74BCE806-5598-4D7A-E040-BB89AD437934

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial